McKESSON CORPORATION
$105.22B- Market cap
- $102.70B
- Debt
- +$6.50B
- Cash
- −$3.98B
Capital structure 94% equity / 6% debt · EV / Revenue 0.26x · EV proxy / EBITDA proxy 16.19x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $102.70B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 · View financials
Decision snapshot: MCK stock price vs ABBV: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ABBV's multiple
Needs ABBV P/E.
Implied fair value · at MCK's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 94% equity / 6% debt · EV / Revenue 0.26x · EV proxy / EBITDA proxy 16.19x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
McKESSON CORPORATION · implied price per share
Bear
$630.54
Base
$765.28
Bull
$951.09
AbbVie Inc. · implied price per share
Bear
$74.44
Base
$92.88
Bull
$117.70
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CARDINAL HEALTH INC
MCK vs CAH
HENRY SCHEIN INC
MCK vs HSIC
PATTERSON COMPANIES, INC.
MCK vs PDCO
Zoetis Inc.
MCK vs ZTS
CVS HEALTH Corp
MCK vs CVS
Pfizer Inc.
MCK vs PFE
Johnson & Johnson
MCK vs JNJ
Merck & Co., Inc.
MCK vs MRK
Eli Lilly and Company
MCK vs LLY
Amgen Inc.
MCK vs AMGN
Gilead Sciences, Inc.
MCK vs GILD
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MCK can sustain faster revenue growth while materially improving margins without sacrificing its low-leverage profile, then consider the name because the current valuation is far below ABBV on every listed multiple; otherwise, the data support only a neutral stance since ABBV's profitability quality is much higher.
MCK trades at a dramatic discount to ABBV across P/E, P/S, EV/EBITDA, and EV/Revenue, but that gap is partly explained by ABBV's much higher margin profile and market-quality premium. MCK's current price of $869.58 sits within its historical band but below ABBV-implied range, suggesting the market is not assigning ABBV-like multiples to MCK's lower-margin distribution model.
Supporting Metrics